This brand name is authorized in Spain, Finland, Israel
The drug RELERT contains one active pharmaceutical ingredient (API):
|
1
Eletriptan
UNII M41W832TA3 - ELETRIPTAN HYDROBROMIDE
|
|
Eletriptan is a selective agonist at the vascular 5-HT1B and neuronal 5-HT1D receptors. Eletriptan also exhibits high affinity for the 5-HT1F receptor which may contribute to its anti-migraine mechanism of action. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| N02CC06 | Eletriptan | N Nervous system → N02 Analgesics → N02C Antimigraine preparations → N02CC Selective serotonin (5HT1) agonists |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: ES | Centro de información online de medicamentos de la AEMPS | Identifier(s): 64122, 64123 |
| Country: FI | Lääkealan turvallisuus- ja kehittämiskeskus | Identifier(s): 553206, 553339 |
| Country: IL | מִשְׂרַד הַבְּרִיאוּת | Identifier(s): 4452, 4453, 4454, 7325, 8901 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
